Dose-response protective effect of salbutamol on methacholine airway responsiveness using pressurized metered dose inhalers and Turbuhalers

Albert G Wong MD, Paul M O’Byrne MB, Christer Lindbladh PhD, Mark D Inman MD PhD, Elisabeth Ståhl PhD, Frederick E Hargreave MD
Asthma Research Group, Department of Medicine, St Joseph’s Hospital and McMaster University, Hamilton, Ontario; and Astra AB Draco, Lund, Sweden

AG Wong, PM O’Byrne, C Lindbladh, MD Inman, E Ståhl, FE Hargreave. Dose-response protective effect of salbutamol on methacholine airway responsiveness using metered dose inhaler and Turbuhaler. Can Respir J 1998;5(2):119-123.

The purpose of this study was to estimate the relative dose potency of salbutamol Turbuhaler compared with salbutamol pressurized metered dose inhaler (pMDI) with respect to the protective effect against methacholine bronchoconstriction. Twenty-three asthmatic subjects with stable asthma participated in the study. Baseline forced expiratory volume in 1 s (FEV₁) was 70% or more of predicted, and baseline methacholine provocative concentration causing a 20% fall in FEV₁ (PC₂₀) was 4 mg/mL or less. The design was randomized, double-blind, double-dummy, crossover and placebo controlled and was conducted over seven study days. On each study day, the subjects inhaled 50 µg or 100 µg of salbutamol via Turbuhaler, 100 µg, 200 µg, 400 µg or 800 µg of salbutamol via pMDI, or placebo in randomized order. PC₂₀ was determined 30 mins after inhalation. Increasing doses of salbutamol pMDI increased the PC₂₀ in a dose-dependent fashion from 3.9 mg/mL after placebo to 13.3 mg/mL after pMDI 100 µg, 19.0 mg/mL after 200 µg, 32.6 mg/mL after 400 µg, and 35.1 mg/mL after 800 µg. The half-maximum response dose for pMDI (ED₅₀) was 104 µg. Salbutamol Turbuhaler 50 µg increased the PC₂₀ to 10.0 mg/mL and 100 µg to 12.6 mg/mL. Salbutamol pMDI 200 µg provided significantly greater protection to methacholine than pMDI 100 µg or Turbuhaler 100 µg and significantly less protection than pMDI 400 µg (P<0.05). This study demonstrates that the relative protective dose potency of inhaled beta-agonists can be determined by comparing their effects on methacholine airway responsiveness. The estimated relative protective dose potency for salbutamol Turbuhaler in comparison with pMDI was 1.38 (95% CI 0.67 to 2.87) at 50 µg and was 0.96 (95% CI 0.56 to 1.64) at 100 µg.

Key Words: Methacholine airway responsiveness, Pressurized metered dose inhaler, Salbutamol, Turbuhaler
**Effet protecteur lié à la dose de salbutamol sur la réactivité des voies respiratoires à la méthacholine; par inhalateur à dose mesurée et par Turbuhaler**

RÉSUMÉ : Le but de cette étude était d’évaluer la puissance comparative de la dose de salbutamol par Turbuhaler ou par inhalateur à dose mesurée pour ce qui est de l’effet protecteur contre la bronchoconstriction induite par la méthacholine. Vingt-trois sujets asthmatiques stables, ont participé à l’étude. Le volume expiratoire forcé au départ, par seconde (VEMS) était de 70 % ou plus de la valeur prévue et la concentration de méthacholine en test de provocation (CP) donnant au départ une baisse de 20 % du VEMS (CP20) a été de 4 mg/mL ou moins. Il s’agissait d’un protocole randomisé à double insu, à double feinte avec permutation des groupes, contrôlé par placebo qui a duré sept jours. Chaque jour, les sujets ont inhalé 50 µg ou 100 µg de salbutamol par Turbuhaler, 100 µg, 200 µg, 400 µg ou 800 µg de salbutamol par inhalateur ou un placebo de façon randomisée. La CP20 a été déterminée 30 minutes après l’inhalation. L’augmentation des doses de salbutamol par inhalateur a baissé la CP20 de façon dose-dépendante de 3,9 mg/mL après le placebo, à 13,3 mg/mL après 100 µg, 19,0 mg/mL après 200 µg, 32,6 mg/mL après 400 µg et 35,1 mg/mL après 800 µg par inhalateur. La moitié de la réponse maximale liée à la dose pour l’inhalateur (DES50) a été de 104 µg. Le salbutamol, 50 µg par Turbuhaler, a augmenté la CP20 à 10,0 mg/mL et 100 µg à 12,6 mg/mL. Le salbutamol 200 µg par inhalateur a conféré une protection significativement plus grande contre la méthacholine, comparativement à 100 µg par inhalateur ou Turbuhaler et une protection significativement moindre de 400 µg par inhalateur (P<0,05). Cette étude confirme que le degré de protection liée à la dose des différents agonistes par inhalation peut être déterminé en comparant leurs effets sur la réactivité des voies respiratoires à la méthacholine. La puissance protectrice relative liée à la dose du salbutamol en Turbuhaler en comparaison avec l’inhalateur a été de 1,38 (IC 95 %, 0,67 à 2,87) avec 50 µg et a été de 0,96 (IC 95 %, 0,56 à 1,64 avec 100 µg).

**PATIENTS AND METHODS**

**Subjects:** Twenty-three adults with asthma volunteered to participate in the study (Table 1). Each subject’s asthma was stable, forced expiratory volume in 1 s (FEV1) was 70% predicted or greater and methacholine provocation concentration to cause a fall in FEV1 of 20% (PC20) was 4 mg/mL or less. In addition, after salbutamol pMDI 200 µg was inhaled, PC20 had to increase at least fourfold. Four subjects were on regular treatment with inhaled steroid (mean 837 µg daily dose) and the dose had been stable for at least three months, and was kept constant throughout the study; no study subjects were on treatment with beta-receptor antagonists, prednisone, antihistamine or immunotherapy. Before each study day the following washout periods were applied: long-acting inhaled beta-agonists for 72 h; oral beta-agonists for 12 h; long-acting oral beta-agonists and methylxanthines for 48 h; anticholinergics for 12 h. No patient was taking regular short-acting beta-agonists at the time of the study. Oral and parenteral corticosteroids were not permitted for one month before visit 1. None of the subjects had symptoms of a respiratory tract infection or exposure to allergens to which they were sensitized for six weeks before or during the study, and none had exercised vigorously before any study visit. The study was approved by the Hospital Research Ethics Committee, written informed consent was obtained for each subject, and the performance of the study was in accord with the principles of the Declaration of Helsinki.

**Study design:** The study was of randomized, double-blind, double-dummy, crossover and placebo controlled design. There were two enrolment days (visits 1 and 2) and seven study days (visits 3 to 9). At visit 1, informed consent was obtained. At visit 2, criteria for entry into the study were
checked. The baseline methacholine PC20 was measured and, if it was 4 mg/mL or less and if no salbutamol was required to treat the methacholine bronchoconstriction, the protective effect of salbutamol pMDI 200 µg was examined. The latter was determined 115 mins after the last inhalation of methacholine, if the FEV1 was greater than 90% of baseline. If the FEV1 was not greater than 90% of baseline, FEV1 was measured every 15 mins until this value was reached. Then salbutamol pMDI 200 µg was inhaled, and 10 mins later the methacholine inhalation test was repeated, beginning with a twofold dilution below the baseline methacholine PC20. If the postsalbutamol methacholine PC20 increased by more than fourfold, the subject was entered into the study.

At visits 3 to 9, the protective effect of the study drugs on the methacholine PC20 was examined, and between these visits, salbutamol 100 µg was allowed only when needed. At each visit, the subject had to be stable as indicated by symptoms, need for salbutamol and an FEV1 that did not vary by more than 10% from visit 2. If FEV1 was lower than this, the subject was re-examined on another day; if it was still abnormal, the subject was withdrawn. The washout period between treatments was two to seven days.

At each visit, the subjects inhaled, in randomized order, salbutamol 50 or 100 µg by Turbuhaler, or 100, 200, 400 or 800 µg by pMDI, or placebo. The active medication and placebo were administered in a double-dummy fashion to maintain blinding. The methacholine inhalation test was repeated 10 mins later, beginning with a twofold dilution below baseline on visit 2 so that the methacholine PC20 value would be determined about 30 mins after inhalation of the test medication. On each day, pulse rate, blood pressure and history of symptoms were recorded before and after the methacholine test.

TABLE 1
Demographic data and baseline pulmonary function of patients participating in the comparison study

| Characteristics          | Mean  | Range   |
|--------------------------|-------|---------|
| Sex (male/female)        | 3:20  |         |
| Age (years)              | 28.3  | 19-50   |
| Height (cm)              | 167   | 152-190 |
| Weight (kg)              | 67.7  | 51-91   |
| Duration of asthma (years)| 13.4  | 1-37    |
| FEV1 (L)                 | 3.13  | 2.35-4.04 |
| FEV1 % predicted         | 92.8  | 75.8-114.2 |
| Slow vital capacity (L)  | 3.93  | 2.66-6.25 |

FEV1: Forced expiratory volume in 1 s

TABLE 2
Individual PC20 comparisons for salbutamol Turbuhaler and metered dose inhaler

| Comparison                  | Ratio (%) | 95% CI     |
|-----------------------------|-----------|------------|
| TBH 50 µg vs pMDI 100 µg    | 75.7      | 55.9-102.6 |
| TBH 100 µg vs pMDI 100 µg   | 95        | 70.0-128.7 |
| TBH 100 µg vs pMDI 200 µg   | 66.3      | 48.9-89.9  |
| pMDI 100 µg vs pMDI 200 µg  | 69.8      | 51.6-94.6  |
| pMDI 200 µg vs pMDI 400 µg  | 58        | 42.8-78.6  |
| pMDI 400 µg vs pMDI 800 µg  | 91.9      | 67.8-124.6 |

PC20: Methacholine provocation concentration to cause a fall in FEV1 of 20%; pMDI: Pressured metered dose inhalers; TBH: Turbuhaler

Spirometric measurements and methacholine tests: The FEV1 and slow vital capacity (SVC) were measured with a Vitalograph Compact Spirometer (Vitagraph Ltd, Buckingham, United Kingdom) according to American Thoracic Society guidelines (9). Methacholine inhalation tests were performed as described by Juniper et al (10) using a Wright Nebulizer (English Wright, Aerosol Medical Ltd, Colchester, United Kingdom) attached to a three-way Hans Rudolph Valve (Hans Rudolph Inc, Missouri), doubling concentrations of methacholine between 0.6 and 256 mg/mL and tidal breathing for 2 mins. The response was measured by change in FEV1 recorded at 30 and 90 s, and then at 3 mins and every 2 mins thereafter until it stopped falling. The fall was recorded between the highest post-test drug, premethacholine value and the lowest postmethacholine value. The results were expressed as the methacholine PC20 obtained from linear interpolation of the last two methacholine doses below and above a 20% fall in FEV1. A methacholine PC20 value was obtained from each subject at each visit, so no data censoring was necessary.

Statistical analysis: A dose-response curve for the pMDI doses was established by estimating a nonlinear regression of log methacholine PC20 versus dose of salbutamol pMDI. The standard dose-response curve was represented by the following equation:

$$\log \text{PC20} = \log \text{PC20 (placebo)} + \max D K(K^E + D^E)$$

where D is the dose of salbutamol, Max is the maximal effect, K is the dose giving 50% of the maximal effect (ED50) and k was the slope parameter. The same model was applied for Turbuhaler, and a different K value was obtained which was called rK. This model assumes that each Turbuhaler dose lies on an individual curve that is parallel to the pMDI dose-effect curve.
response curve. The relative dose potency was represented by the r value. Analysis of variance was used to obtain period-adjusted mean values and a correct variability. These data were then analyzed using nonlinear regression in order to estimate the r value and give confidence limits. For all analyses, a probability value of $P<0.05$ was considered significant. The adverse events were analyzed by means of descriptive statistics and qualitative analysis.

**RESULTS**

The mean baseline FEV$_1$ was 3.13 L, and the SVC was 3.93 L. The mean difference in baseline FEV$_1$ was 7.0% (range 3.0% to 13.2%) with a coefficient of variation (CV) of 2.7% (range 1.4% to 5.7%). The baseline PC$_{20}$ was 1.8 mg/mL (range 0.4 to 3.8) and increased by 11.3-fold after two times 100 µg salbutamol pMDI to 17.0 mg/mL (range 4.6 to 56).

Increasing doses of salbutamol delivered by pMDI increased the methacholine PC$_{20}$ in a dose-dependent fashion. The methacholine PC$_{20}$ after placebo was 3.90 mg/mL (CV 128%). This increased to 13.3 mg/mL (CV 135%) after salbutamol 100 µg, to 19.0 mg/mL (CV 126%) after salbutamol 200 µg, to 32.6 mg/mL (CV 136%) after salbutamol 400 µg and to 35.1 mg/mL (CV 132%) after salbutamol 800 µg (Figure 1). The half-maximum response to pMDI (ED$_{50}$) was 104 µg (95% CI 63 to 171). Salbutamol delivered via Turbuhaler increased the methacholine PC$_{20}$ to 10.0 mg/mL (CV 155%) after 50 µg and to 12.6 mg/mL (CV 124%) after the 100 µg dose. Salbutamol pMDI 200 µg provided significantly greater protection to methacholine than with either pMDI 100 µg or Turbuhaler 100 µg and was significantly different from pMDI 400 µg ($P<0.05$) (Table 2). There were no statistically significant differences when comparing Turbuhaler 100 µg with pMDI 100 µg, or Turbuhaler 50 µg with pMDI 100 µg. No further significant increase in PC$_{20}$ was seen at 800 µg compared with 400 µg of salbutamol pMDI.

Nonlinear regression analysis revealed a relative dose potency of 1.38 (95% CI 1.067 to 2.87) for Turbuhaler 50 µg versus pMDI 50 µg, and 0.96 (95% CI 0.56 to 1.64) for Turbuhaler 100 µg versus pMDI 100 µg. This means that 50 µg from Turbuhaler on average would give the same protection against methacholine as 68.5 µg from pMDI (95% CI 33.6 to 105.9). Similarly, 100 µg from Turbuhaler on average would give the same protection as 96.9 µg from pMDI (95% CI 54.1 to 144.0).

Salbutamol was well tolerated at all doses. There were no significant adverse effects nor were there any significant changes in pulse rate or blood pressure.

**DISCUSSION**

This study has demonstrated the use of bronchoprotection against methacholine challenge as a method to determine relative protective potencies of different salbutamol formulations. The study suggests that the relative dose potency for salbutamol Turbuhaler was 1.36 at the 50 µg dose compared with pMDI and 0.96 at the 100 µg dose compared with pMDI.

A dose-response curve of methacholine PC$_{20}$ versus doses of salbutamol was obtained for salbutamol pMDI. The ED$_{50}$ response occurred at 104 µg which was close to the lowest dose of 100 µg. Methacholine PC$_{20}$ increased significantly at doses of 100 µg, 200 and 400 µg, but did not change further with 800 µg. The demonstration of ED$_{50}$ close to the lowest dose delivered by pMDI was unexpected and indicates that a major portion of the dose-response curve is located at 100 µg and below. Therefore, future studies could incorporate the use of lower doses of salbutamol pMDI (eg, 50 µg) to measure this part of the curve more accurately.

Studies have shown that Turbuhaler is effective in delivering a higher proportion of the nominal dose to the lungs compared with pMDI (11,12). In the present study, the relative dose protective potency of 0.96 for Turbuhaler 100 µg was not significantly different from that of salbutamol pMDI. Thus, Turbuhaler 100 µg would produce the same amount of bronchoprotection against inhaled methacholine as the pMDI. One explanation for this similarity could be a ‘ceiling effect’ where both devices produce the maximal possible bronchoprotection and, therefore, do not allow differences to be demonstrated between these devices. This is clearly not the case because a dose of 100 µg is close to the ED$_{50}$. This result does demonstrate the advantage of constructing dose-response curves, as was done in this study, because comparison of single doses from the two devices could not have eliminated this possibility.

Mildly asthmatic subjects (baseline methacholine PC$_{20}$ of 1.8 mg/mL) with normal baseline pulmonary function were selected for this study. Dose-response curves may differ for asthmatics with moderate or severe asthma, or heightened
airway responsiveness. In these patients, pretreatment with salbutamol may produce additional bronchodilation that may interfere with the bronchoconstricting effects of methacholine. It is also possible that methacholine exerts its effect at locations different from the site of action of salbutamol when given by either Turbuhaler or pMDI or that there are differences in lung distribution pattern between Turbuhaler and pMDI. Several factors, such as inhalation pattern, airway calibre and degree of obstruction, have been shown to influence the site of deposition in the lung (13,14).

Because methacholine exerts its effects on the central airways, which are the main sites of the cholinergic receptors (15), the bronchodilating effects of a medication may not be representative of the protection it provides against a cholinergic bronchoconstrictor mediator, such as methacholine. This caveat also applies when comparing the results of the present study with those achieved using other provocation agents acting through other mechanisms.

**CONCLUSIONS**
This study has demonstrated that the relative dose protective potency of salbutamol given via Turbuhaler and via pMDI may be determined by comparing its effects on methacholine airway responsiveness. The relation between dose-protective potency obtained using other provocation agents, as well as the relation between protective and bronchodilating potency, needs to be further investigated.

**ACKNOWLEDGEMENTS:** Supported by Astra AB Draco.

**REFERENCES**
1. Molina MJ, Rowland FS. Stratospheric sink for chlorofluoromethanes: chlorine atom-catalysed destruction of ozone. Nature 1974;249:810-2.
2. Jackson L, Ståhl E, Holgate ST. Terbutaline via pressurised metered dose inhaler (pMDI) and Turbuhaler in highly reactive asthmatic patients. Eur Respir J 1994;7:1598-601.
3. Harvey J, Williams JG. Randomised cross-over comparison of five inhaler systems for bronchodilator therapy. Br J Clin Pract 1992;46:249-51.
4. Lofdahl CG, Andersson L, Carlsson LG, et al. Lower nominal dose required of inhaled salbutamol via Turbuhaler® compared with pressurized metered dose inhaler, for the same bronchodilating effect. Am J Respir Crit Care Med 1994;149:A219. (Abst)
5. Jansson B, Bondesson E. Relative tolerability of salbutamol inhaled via Turbuhaler® and via a pressurized metered dose inhaler (pMDI). Eur Respir J 1994;7:50s. (Abst)
6. Borgström L, Derom E, Ståhl E, Wåhlin-Boll E, Pauwels R. The inhalation device influences lung deposition and bronchodilating effect of terbutaline. Am J Respir Crit Care Med 1996;153:1636-40.
7. Tønnesen F, Laursen LC, Evald T, Ståhl E, Ibsen T. Bronchodilating effect of terbutaline powder in acute bronchial obstruction. Chest 1994;105:697-700.
8. Tattersfield AE. Effect of beta-agonists and anti-cholinergic drugs on bronchial reactivity. Am Rev Respir Dis 1987;136:S64-8.
9. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987;136:225-44.
10. Juniper EF, Cockcroft DW, Hargrave FE. Histamine and Methacholine Inhalation Tests: A Laboratory Tidal Breathing Protocol, 2nd edn. Lund: Astra Draco AB, 1994.
11. Borgström L, Newman S. Total and regional lung deposition of terbutaline sulphate inhaled via a pressurized MDI or via Turbuhaler. Int J Pharm 1993;97:47-53.
12. Thorsson L, Edsbäcker S, Conradsson TB. Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered dose inhaler pMDI. Eur Respir J 1994;7:1839-44.
13. Santolicandro A, DiMauro M, Storti S, et al. Pulmonary redistribution of inhaled budesonide after bronchodilation. Eur Respir J 1994;7:366S. (Abst)
14. Dolovich M, Ryan G, Newhouse MT. Aerosol penetration into the lung. Influence on airway response. Chest 1981;80:834-6.
15. Barnes PJ. State of the art: Neural control of human airways in health and disease. Am Rev Respir Dis 1986;134:1289-314.
